Key facts
- It has raised $50.0M; the latest was Early Stage VC ($50.0M) in Nov 2025.
- Notable investors include Obuda Uni Venture Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Mycellen
- ·The full record, as it builds
Funding rounds
No funding rounds for Mycellen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mycellen
Developer of a dietary supplement designed for supporting cellular energy and healthy aging. The company offers a blend of Nicotinamide Mononucleotide (NMN), Vitamin D3, Trans-Resveratrol, and Bio-Quercetin to help increase NAD+ levels and support vital functions, enabling health-conscious consumers to enhance energy, immunity, and overall well-being through scientifically informed
- Sector
- Consumer Products and Services (B2C)
- HQ
- Pest, Hungary
- Founded
- 2021
- Website
- mycellen.com/
- Ownership
- Privately Held (backing)
Mycellen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mycellen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mycellen in its N-PORT filings yet. We sweep new filings monthly.